ArticleImmunity, inflammation and disease2021

Ruxolitinib inhibits poly(I:C) and type 2 cytokines-induced CCL5 production in bronchial epithelial cells: A potential therapeutic agent for severe eosinophilic asthma.

Mitsuru Sada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.